MedTrace Logo

The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens

NCT02413021 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-02-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether deferasirox is effective in the treatment of acute lymphatic leukemia (ALL) and acute Myeloid leukemia (AML).

Conditions

Interventions

DRUG

Cytarabine

20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle

DRUG

Deferasirox

20 mg/kg ,oral, per day

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Valiollah Mehrzad, MD · Seyyed-alshohada hospital of Isfahan

  • Shaghayegh Haghjoo Javanmard, MD, PHD · Applied Physiology Research Center

  • Mahnaz Danesh, MD · Seyyed-alshohada hospital of Isfahan

  • Alireza Eishi, Med student · Applied Physiology Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-08-31
Completion
2016-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02413021 on ClinicalTrials.gov